Smart blood cell and microvesicle-based Trojan horse drug delivery

Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine

Yu Wen Wu, Hadi Goubran, Jerard Seghatchian, Thierry Burnouf

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Therapeutic and diagnostic applications of nanomedicine are playing increasingly important roles in human health. Various types of synthetic nanoparticles, including liposomes, micelles, and other nanotherapeutic platforms and conjugates, are being engineered to encapsulate or carry drugs for treating diseases such as cancer, cardiovascular disorders, neurodegeneration, and inflammations. Nanocarriers are designed to increase the half-life of drugs, decrease their toxicity and, ideally, target pathological sites. Developing smart carriers with the capacity to deliver drugs specifically to the microenvironment of diseased cells with minimum systemic toxicity is the goal. Blood cells, and potentially also the liposome-like micro- and nano-vesicles they generate, may be regarded as ideally suited to perform such specific targeting with minimum immunogenic risks. Blood cell membranes are "decorated" with complex physiological receptors capable of targeting and communicating with other cells and tissues and delivering their content to the surrounding pathological microenvironment. Blood cells, such as erythrocytes, have been developed as permeable carriers to release drugs to diseased tissues or act as biofactory allowing enzymatic degradation of a pathological substrate. Interestingly, attempts are also being made to improve the targeting capacity of synthetic nanoparticles by "decorating" their surface with blood cell membrane receptor-like biochemical structures. Research is needed to further explore the benefits that blood cell-derived microvesicles, as a Trojan horse delivery systems, can bring to the arsenal of therapeutic micro- and nanotechnologies. This short review focuses on the therapeutic roles that red blood cells and platelets can play as smart drug-delivery systems, and highlights the benefits that blood transfusion expertise can bring to this exciting and novel biomedical engineering field.

Original languageEnglish
Pages (from-to)309-318
Number of pages10
JournalTransfusion and Apheresis Science
Volume54
Issue number2
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Nanomedicine
Biomedical Engineering
Blood Transfusion
Blood Cells
Pharmaceutical Preparations
Liposomes
Nanoparticles
Erythrocytes
Cell Membrane
Microtechnology
Cellular Microenvironment
Nanotechnology
Micelles
Drug Delivery Systems
Half-Life
Therapeutics
Blood Platelets
Inflammation
Health
Research

Keywords

  • Drug carriers
  • Drug delivery
  • Microvescicles
  • Platelets
  • Red blood cells

ASJC Scopus subject areas

  • Hematology

Cite this

Smart blood cell and microvesicle-based Trojan horse drug delivery : Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. / Wu, Yu Wen; Goubran, Hadi; Seghatchian, Jerard; Burnouf, Thierry.

In: Transfusion and Apheresis Science, Vol. 54, No. 2, 01.04.2016, p. 309-318.

Research output: Contribution to journalReview article

@article{d50d57b3b95646b88241b582ff2b94df,
title = "Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine",
abstract = "Therapeutic and diagnostic applications of nanomedicine are playing increasingly important roles in human health. Various types of synthetic nanoparticles, including liposomes, micelles, and other nanotherapeutic platforms and conjugates, are being engineered to encapsulate or carry drugs for treating diseases such as cancer, cardiovascular disorders, neurodegeneration, and inflammations. Nanocarriers are designed to increase the half-life of drugs, decrease their toxicity and, ideally, target pathological sites. Developing smart carriers with the capacity to deliver drugs specifically to the microenvironment of diseased cells with minimum systemic toxicity is the goal. Blood cells, and potentially also the liposome-like micro- and nano-vesicles they generate, may be regarded as ideally suited to perform such specific targeting with minimum immunogenic risks. Blood cell membranes are {"}decorated{"} with complex physiological receptors capable of targeting and communicating with other cells and tissues and delivering their content to the surrounding pathological microenvironment. Blood cells, such as erythrocytes, have been developed as permeable carriers to release drugs to diseased tissues or act as biofactory allowing enzymatic degradation of a pathological substrate. Interestingly, attempts are also being made to improve the targeting capacity of synthetic nanoparticles by {"}decorating{"} their surface with blood cell membrane receptor-like biochemical structures. Research is needed to further explore the benefits that blood cell-derived microvesicles, as a Trojan horse delivery systems, can bring to the arsenal of therapeutic micro- and nanotechnologies. This short review focuses on the therapeutic roles that red blood cells and platelets can play as smart drug-delivery systems, and highlights the benefits that blood transfusion expertise can bring to this exciting and novel biomedical engineering field.",
keywords = "Drug carriers, Drug delivery, Microvescicles, Platelets, Red blood cells",
author = "Wu, {Yu Wen} and Hadi Goubran and Jerard Seghatchian and Thierry Burnouf",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.transci.2016.04.013",
language = "English",
volume = "54",
pages = "309--318",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Smart blood cell and microvesicle-based Trojan horse drug delivery

T2 - Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine

AU - Wu, Yu Wen

AU - Goubran, Hadi

AU - Seghatchian, Jerard

AU - Burnouf, Thierry

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Therapeutic and diagnostic applications of nanomedicine are playing increasingly important roles in human health. Various types of synthetic nanoparticles, including liposomes, micelles, and other nanotherapeutic platforms and conjugates, are being engineered to encapsulate or carry drugs for treating diseases such as cancer, cardiovascular disorders, neurodegeneration, and inflammations. Nanocarriers are designed to increase the half-life of drugs, decrease their toxicity and, ideally, target pathological sites. Developing smart carriers with the capacity to deliver drugs specifically to the microenvironment of diseased cells with minimum systemic toxicity is the goal. Blood cells, and potentially also the liposome-like micro- and nano-vesicles they generate, may be regarded as ideally suited to perform such specific targeting with minimum immunogenic risks. Blood cell membranes are "decorated" with complex physiological receptors capable of targeting and communicating with other cells and tissues and delivering their content to the surrounding pathological microenvironment. Blood cells, such as erythrocytes, have been developed as permeable carriers to release drugs to diseased tissues or act as biofactory allowing enzymatic degradation of a pathological substrate. Interestingly, attempts are also being made to improve the targeting capacity of synthetic nanoparticles by "decorating" their surface with blood cell membrane receptor-like biochemical structures. Research is needed to further explore the benefits that blood cell-derived microvesicles, as a Trojan horse delivery systems, can bring to the arsenal of therapeutic micro- and nanotechnologies. This short review focuses on the therapeutic roles that red blood cells and platelets can play as smart drug-delivery systems, and highlights the benefits that blood transfusion expertise can bring to this exciting and novel biomedical engineering field.

AB - Therapeutic and diagnostic applications of nanomedicine are playing increasingly important roles in human health. Various types of synthetic nanoparticles, including liposomes, micelles, and other nanotherapeutic platforms and conjugates, are being engineered to encapsulate or carry drugs for treating diseases such as cancer, cardiovascular disorders, neurodegeneration, and inflammations. Nanocarriers are designed to increase the half-life of drugs, decrease their toxicity and, ideally, target pathological sites. Developing smart carriers with the capacity to deliver drugs specifically to the microenvironment of diseased cells with minimum systemic toxicity is the goal. Blood cells, and potentially also the liposome-like micro- and nano-vesicles they generate, may be regarded as ideally suited to perform such specific targeting with minimum immunogenic risks. Blood cell membranes are "decorated" with complex physiological receptors capable of targeting and communicating with other cells and tissues and delivering their content to the surrounding pathological microenvironment. Blood cells, such as erythrocytes, have been developed as permeable carriers to release drugs to diseased tissues or act as biofactory allowing enzymatic degradation of a pathological substrate. Interestingly, attempts are also being made to improve the targeting capacity of synthetic nanoparticles by "decorating" their surface with blood cell membrane receptor-like biochemical structures. Research is needed to further explore the benefits that blood cell-derived microvesicles, as a Trojan horse delivery systems, can bring to the arsenal of therapeutic micro- and nanotechnologies. This short review focuses on the therapeutic roles that red blood cells and platelets can play as smart drug-delivery systems, and highlights the benefits that blood transfusion expertise can bring to this exciting and novel biomedical engineering field.

KW - Drug carriers

KW - Drug delivery

KW - Microvescicles

KW - Platelets

KW - Red blood cells

UR - http://www.scopus.com/inward/record.url?scp=84969961766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969961766&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2016.04.013

DO - 10.1016/j.transci.2016.04.013

M3 - Review article

VL - 54

SP - 309

EP - 318

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 2

ER -